Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study - PubMed
7 hours ago
- #real-world study
- #prostate cancer
- #androgen receptor inhibitors
- The DEAR-EXT study analyzed androgen receptor inhibitors (ARIs) in US patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
- Darolutamide showed lower risks of discontinuation and progression to metastatic disease compared to enzalutamide and apalutamide.
- The study included 1375 patients, with darolutamide (41%), enzalutamide (44%), and apalutamide (15%) as treatment groups.
- Darolutamide had significantly lower adjusted risks of discontinuation and progression to mCRPC compared to other ARIs.
- Metastasis-free survival (MFS) was longer with darolutamide, with estimated rates of 72.3% at 24 months and 60.2% at 36 months.
- Darolutamide also showed higher PSA response rates, improved survival, and fewer adverse events in real-world settings.
- The study highlights darolutamide's potential to enhance patient outcomes in nmCRPC.